SSA
ADVM

Schonfeld Strategic Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,120
Closed -$18.1K – 2045
2022
Q4 		$18.1K Sell
3,120
-2,880
-48% -$21.8K ﹤0.01% 2331
2022
Q3 		$57K Hold
6,000
– – ﹤0.01% 2624
2022
Q2 		$72K Hold
6,000
– – ﹤0.01% 2186
2022
Q1 		$79K Buy
+6,000
New +$87.8K ﹤0.01% 2277
2020
Q4 		– Sell
-14,230
Closed -$1.47M – 1532
2020
Q3 		$1.47M Buy
14,230
+8,630
+154% +$1.29M 0.03% 599
2020
Q2 		$1.17M Buy
5,600
+4,406
+369% +$780K 0.03% 566
2020
Q1 		$117K Sell
1,194
-8,715
-88% -$1.02M 0.01% 984
2019
Q4 		$1.14M Sell
9,909
-58,761
-86% -$5.18M 0.03% 480
2019
Q3 		$3.74M Buy
+68,670
New +$7.74M 0.11% 206
2016
Q2 		– Sell
-1,000
Closed -$52K – 419
2016
Q1 		$52K Buy
+1,000
New +$55.8K 0.02% 296

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Schonfeld Strategic Advisors's ADVM Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Adverum Biotechnologies (ADVM) in Q1 2023, closing a stake of 3,120 shares — an estimated $18.1K sold.

Schonfeld Strategic Advisors first reported a position in ADVM in Q1 2016 and held it in 10 quarters. The position peaked at $3.74M in Q3 2019. 55 funds tracked by Wall St. Rank hold ADVM as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Adverum Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,120 Adverum Biotechnologies shares in Q1 2023, an estimated $18.1K.
  • Schonfeld Strategic Advisors first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Adverum Biotechnologies position peaked at $3.74M in Q3 2019.
  • 55 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.